NasdaqGS - Nasdaq Real Time Price USD

Praxis Precision Medicines, Inc. (PRAX)

54.80

+1.92

(+3.63%)

At close: April 26 at 4:00 PM EDT

54.80

0.00

(0.00%)

After hours: April 26 at 4:16 PM EDT

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showca

GlobeNewswire 14 days ago
Praxis Precision Medicines to Participate in Upcoming April Conferences

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April. Praxis management will participate in a fireside chat at the Needham 23rd Annual Healthcare Conference, taking place vi

GlobeNewswire 21 days ago
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stoc

GlobeNewswire 24 days ago
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funde

GlobeNewswire 30 days ago
Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering

GlobeNewswire 30 days ago
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures Praxis plans to initiate an efficacy study in focal onset epilepsy in the second half of 2024 BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company

GlobeNewswire last month
Praxis Precision Medicines to Host PRAX-628 Program Update

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitati

GlobeNewswire last month
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024 Topline results from the PRAX-628 study in epilepsy patients with photo-paroxysmal response (PPR) expected in 1Q 2024; preliminary analysis of 15 mg cohort exceeded expectations Tolerability and efficacy results from Part 1 of the EMBRAVE study of elsune

GlobeNewswire last month
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the TD Cowen 44th Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024. In addition to conducting one-on-one investor meetin

GlobeNewswire last month
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50 and, in lieu of shares of common stock, pre-funded

GlobeNewswire 3 months ago
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort Enrollment for both ulixacaltamide Phase 3 Studies in the Essential3 program on track to be completed in 1H 2024 with topline results in 2H 2024 Recently announced licensing partnership with Tenacia Biotechnology to develop and commercialize ulixacaltamide in Greater China with tota

GlobeNewswire 3 months ago
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of $15 million and is eligible to receive up to $264 million in milestone payments as well as tiered royalties BOSTON and SHANGHAI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen

GlobeNewswire 3 months ago
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting,

GlobeNewswire 4 months ago
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast throug

GlobeNewswire 5 months ago
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental a

GlobeNewswire 5 months ago
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development Cash of $101.1 million as of September 30, 2023 supports runway into Q1 2025 BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CN

GlobeNewswire 5 months ago
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a panel discussion titled “CNS Companies Looking To Address High Unmet High Prevalence and High Value Diseases” at the Truist Securities BioPharma Sy

GlobeNewswire 5 months ago
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insigh

GlobeNewswire 6 months ago
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a R&D Day on Monday, October 2, at 9:00 a.m. EDT, virtually and in person in New York City. During the event, Praxis’ management team will review progress from its pi

GlobeNewswire 6 months ago
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 12 p.m. EDT. The event will be available vi

GlobeNewswire 7 months ago

Performance Overview

Return	PRAX	S&P 500
YTD	+145.96%	+6.92%
1-Year	+251.28%	+25.26%
3-Year	-86.92%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Praxis Precision Medicines to Host PRAX-628 Program Update

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

Performance Overview